Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies

Virology

Volumn 449, Issue , 2014, Pages 304-316

  Wang, Joshua W ^a   Jagu, Subhashini ^a   Kwak, Kihyuck ^a   Wang, Chenguang ^a   Peng, Shiwen ^a   Kirnbauer, Reinhard ^c   Roden, Richard B S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Carrageenan; Furin; Gamma secretase; Heparin; Human papillomavirus (HPV); Infectious intermediate; L2; Minor capsid protein; Neutralization; Papillomavirus

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; CARRAGEENAN; EPITOPE; FURIN; GAMMA SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VACCINATION; VIRION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; PAPILLOMAVIRIDAE;

CARRAGEENAN; FURIN; GAMMA SECRETASE; HEPARIN; HUMAN PAPILLOMAVIRUS (HPV); INFECTIOUS INTERMEDIATE; L2; MINOR CAPSID PROTEIN; NEUTRALIZATION; PAPILLOMAVIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CROSS REACTIONS; FURIN; HUMANS; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84890725011     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.10.038     Document Type: Article

References (57)

1. Anderson E.D., VanSlyke J.K., Thulin C.D., Jean F., Thomas G. Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. EMBO J. 1997, 16:1508-1518.
2. Bourne G.L., Grainger D.J. Development and characterisation of an assay for furin activity. J. Immunol. Methods 2011, 364:101-108.
3. Buck C.B., Cheng N., Thompson C.D., Lowy D.R., Steven A.C., Schiller J.T., Trus B.L. Arrangement of L2 within the papillomavirus capsid. J. Virol. 2008, 82:5190-5197.
4. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004, 78:751-757.
5. Buck C.B., Thompson C.D., Pang Y.Y., Lowy D.R., Schiller J.T. Maturation of papillomavirus capsids. J. Virol. 2005, 79:2839-2846.
6. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2:e69.
7. Buck C.B., Trus B.L. The papillomavirus virion: a machine built to hide molecular Achilles' heels. Adv. Exp. Med. Biol. 2012, 726:403-422.
8. Carter J.J., Yaegashi N., Jenison S.A., Galloway D.A. Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology 1991, 182:513-521.
9. Cerqueira C., Liu Y., Kuhling L., Chai W., Hafezi W., van Kuppevelt T.H., Kuhn J.E., Feizi T., Schelhaas M. Heparin increases the infectivity of human papillomavirus Type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell. Microbiol. 2013.
10. Christensen N.D., Kreider J.W., Kan N.C., DiAngelo S.L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991, 181:572-579.
11. Cladel N.M., Budgeon L.R., Cooper T.K., Balogh K.K., Hu J., Christensen N.D. Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus. J. Virol. 2013, 87:9391-9395.
12. Conway M.J., Alam S., Christensen N.D., Meyers C. Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines. Virology 2009, 393:295-303.
13. Conway M.J., Alam S., Ryndock E.J., Cruz L., Christensen N.D., Roden R.B., Meyers C. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J. Virol. 2009, 83:10515-10526.
14. Conway M.J., Cruz L., Alam S., Christensen N.D., Meyers C. Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PloS One 2011, 6:e16405.
15. Cruz L., Meyers C. Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PloS One 2013, 8:e68379.
16. Culp T.D., Cladel N.M., Balogh K.K., Budgeon L.R., Mejia A.F., Christensen N.D. Papillomavirus particles assembled in 293TT cells are infectious in vivo. J. Virol. 2006, 80:11381-11384.
17. Day P.M., Gambhira R., Roden R.B., Lowy D.R., Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J. Virol. 2008, 82:4638-4646.
18. Day P.M., Lowy D.R., Schiller J.T. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 2008, 82:12565-12568.
19. Day P.M., Pang Y.Y., Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin. Vaccine Immunol. 2012, 19:1075-1082.
20. Day P.M., Pang Y.Y.S., Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin. Vaccine Immunol. 2012, 19:1075-1082.
21. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
22. Doorbar J., Gallimore P.H. Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J. Virol. 1987, 61:2793-2799.
23. Drewinko B., Romsdahl M.M., Yang L.Y., Ahearn M.J., Trujillo J.M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976, 36:467-475.
24. Esko J.D., Stewart T.E., Taylor W.H. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA 1985, 82:3197-3201.
25. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., Alphs H., Culp T., Christensen N.D., Roden R.B. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 2007, 81:13927-13931.
26. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 1995, 63:82-87.
27. Holmgren S.C., Patterson N.A., Ozbun M.A., Lambert P.F. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J. Virol. 2005, 79:3938-3948.
28. Huang H.S., Buck C.B., Lambert P.F. Inhibition of gamma secretase blocks HPV infection. Virology 2010, 407:391-396.
29. Jagu S., Kwak K., Karanam B., Huh W.K., Damotharan V., Chivukula S.V., Roden R.B. Optimization of multimeric human papillomavirus L2 vaccines. PloS One 2013, 8:e55538.
30. Jagu S., Kwak K., Schiller J.T., Lowy D.R., Kleanthous H., Kalnin K., Wang C., Wang H.K., Chow L.T., Huh W.K., Jaganathan K.S., Chivukula S.V., Roden R.B. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J. Virol. 2013, 87:6127-6136.
31. Jin X.W., Cowsert L.M., Pilacinski W.P., Jenson A.B. Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies. J. Gen. Virol. 1989, 70(Pt 5):1133-1140.
32. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 2009, 83:2067-2074.
33. Karanam B., Peng S., Li T., Buck C., Day P.M., Roden R.B. Papillomavirus infection requires gamma secretase. J. Virol. 2010, 84:10661-10670.
34. Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T., Day P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA 2009, 106:20458-20463.
35. Komly C.A., Breitburd F., Croissant O., Streeck R.E. The L2 open reading frame of human papillomavirus type 1a encodes a minor structural protein carrying type-specific antigens. J. Virol. 1986, 60:813-816.
36. Kreider J.W., Cladel N.M., Patrick S.D., Welsh P.A., DiAngelo S.L., Bower J.M., Christensen N.D. High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA. J. Virol. Methods 1995, 55:233-244.
37. Liu W.J., Gissmann L., Sun X.Y., Kanjanahaluethai A., Muller M., Doorbar J., Zhou J. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 1997, 227:474-483.
38. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12:781-789.
39. Marais D., Gawarecki D., Allan B., Ahmed K., Altini L., Cassim N., Gopolang F., Hoffman M., Ramjee G., Williamson A.L. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir. Ther. 2011, 16:1219-1226.
40. McLaughlin-Drubin M.E., Christensen N.D., Meyers C. Propagation, infection, and neutralization of authentic HPV16 virus. Virology 2004, 322:213-219.
41. Meyers C., Frattini M.G., Hudson J.B., Laimins L.A. Biosynthesis of human papillomavirus from a continuous cell-line upon epithelial differentiation. Science 1992, 257:971-973.
42. Parkin D.M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S3/11-25.
43. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., Kruger Kjaer S., Lowy D.R., Schiller J.T. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
44. Pyeon D., Lambert P.F., Ahlquist P. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. USA 2005, 102:9311-9316.
45. Richards K.F., Bienkowska-Haba M., Dasgupta J., Chen X.S., Sapp M. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J. Virol. 2013, 87:11426-11437.
46. Rippe R.A., Meinke W.J. Identification and characterization of the BPV-2 L2 protein. Virology 1989, 171:298-301.
47. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., Lowy D.R., Schiller J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13:857-861.
48. Roden R.B., Yutzy W.H.4th, Fallon R., Inglis S., Lowy D.R., Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254-257.
49. Rose R.C., Bonnez W., Strike D.G., Reichman R.C. Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J. Gen. Virol. 1990, 71(Pt 11):2725-2729.
50. Schellenbacher C., Roden R., Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 2009, 83:10085-10095.
51. Surviladze Z., Dziduszko A., Ozbun M.A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 2012, 8:e1002519.
52. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev.Mol. Cell Biol. 2002, 3:753-766.
53. Tumban E., Peabody J., Peabody D.S., Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PloS One 2011, 6:e23310.
54. Vey M., Schafer W., Berghofer S., Klenk H.D., Garten W. Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J. Cell Biol. 1994, 127:1829-1842.
55. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., Salmeron J., Chow S.N., Apter D., Kitchener H., Teixeira J.C., Skinner S.R., Jaisamrarn U., Limson G., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.A., Bosch F.X., Harper D.M., Huh W., Hardt K., Zahaf T., Descamps D., Struyf F., Dubin G., Lehtinen M. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13:100-110.
56. Wu, W., Kwak, K., Jagu, S., Huh, W.K., Roden, R.B.S., 2012. The Fc Domain Plays an Important Role in Neutralization and Protection of Mice from Vaginal HPV16 Challenge by Monoclonal Antibody WW1. In: Proceedings of the 28th International Papillomavirus Meeting, Puerto Rico, November 2012, Abstract B06-086.
57. Xi S.Z., Banks L.M. Baculovirus expression of the human papillomavirus type 16 capsid proteins: detection of L1-L2 protein complexes. J. Gen. Virol. 1991, 72(Pt 12):2981-2988.